Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pirfenidone in Adult Hospitalized Patients With COVID-19.

NCT05713292 is registered in ClinicalTrials.gov with Capital Medical University as lead sponsor.

NCT NCT05713292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05713292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pirfenidone in Adult Hospitalized Patients With COVID-19.
Lead sponsor
Capital Medical University
Phase
Phase 3
Overall status
Completed
Start date
December 1, 2022
Completion date
March 30, 2023
Enrollment
168 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pneumonia